Corticotropin-releasing hormone (CRH), a hypothalamic neuropeptide involved in the regulation of ACTH secretion, has been detected by RIA in extracts of human placenta. We wished to determine whether this immunoreactive substance is a product of CRH gene expression in the placenta. We have found authentic human CRH (hCRH) mRNA in human placental tissue that is similar in size to hypothalamic CRH mRNA. Furthermore, the transcriptional initiation site for placental hCRH mRNA is identical to that previously predicted for hypothalamic hCRH mRNA, 23-26 nucleotides downstream from a canonical promoter element. Placental hCRH mRNA increases more than 20-fold in the 5 wk preceding parturition, in parallel with a rise in placental hCRH peptide content. These data strongly suggest that the hCRH gene is expressed in the placenta and that this expression changes dramatically during gestation.
Introduction
Corticotropin-releasing hormone (CRH)' is a 41-amino acid neuropeptide synthesized in the paraventricular nucleus of the hypothalamus and released into the hypophyseal-portal system in response to stress (1) . It has a major role in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis via its stimulation of proopiomelanocortin gene expression (2) and ACTH release (1) in the anterior pituitary. The expression of hypothalamic CRH is negatively regulated by glucocorticoid hormones (3, 4) .
A substance detected by antisera to human CRH (hCRH) has been found in extracts of human placenta (5) , and in maternal (6) (7) (8) (9) and fetal (7) (8) (9) plasma. This material is indistinguishable from native hCRH, both in its apparent size (6, 7, 9) and biological properties (5, 9) . These studies suggest, but do not definitively demonstrate, that hCRH is synthesized in 1 . Abbreviations used in this paper: 02M, #2 microglobulin; CRH, corticotropin-releasing hormone; hCG-a, human chorionic gonadotropin alpha subunit; hCRH, human CRH; HPA, hypothalamic-pituitary-adrenal. human placenta. To determine this directly, we examined hCRH gene expression in human placental tissue. Using genomic CRH probes isolated from man and rat, we detected hCRH mRNA in placenta, and determined that it is similar in size to hypothalamic CRH mRNA. Furthermore, whereas the level of placental hCRH mRNA is very low during the first 30 wk of gestation, it increases over 20- (13) (kindly provided by J. Seidman, Harvard University) was inserted into the Pst I site ofBluescribe, and the #2M antisense cRNA probe was synthesized using T3 RNA polymerase. Radioactively labeled cRNA probes were synthesized as described (14) using except that unincorporated nucleotide was separated from RNA by affinity chromatography on an Elutip column (Schleicher and Schuell, Inc., Keene, NH).
A synthetic oligonucleotide, P1, which was 22 nucleotides in length and synthesized by the phosphite triester method (15), was used in a primer extension analysis of the 5' end of human placental CRH mRNA ( RNA filter (Northern) blot hybridization analysis. Total RNA was extracted (18) and 10-Ag aliquots (unless otherwise noted) were subjected to Northern blot analysis using 1.4% agarose gels containing 2.2 M formaldehyde (19). After electrophoresis, RNA was transferred to nitrocellulose (20) and hybridized at 65°C to 1 X 106 cpm of cRNA probe for 18 h. Filters were washed at 65°C in two changes of 0.1% SDS, 15 mM NaCl, 1.5 mM sodium citrate, and were then exposed to Kodak XAR5 film at -80°C. The amount of (32M mRNA encoding a constitutively expressed component of the class I cell surface antigen (21) was determined by separately probing blots with the #2M probe. A semiquantitative assessment of the mRNA detected in the RNA filter hybridization assay was performed by densitometric scanning of autoradiograms of Northern blots using an Ultrascan densitometer (LKB Instruments, Inc., Gaithersburg, MD) (22) . The level of hCRH mRNA in each sample was corrected for differences in recovery based on the amount of j2M mRNA detected. Primer extension analysis of the S' end ofplacental hCRH mRNA. Primer extension analysis of the 5' end of placental hCRH mRNA was performed as previously described (23) except for the following modifications. 5 jug of total placental RNA was mixed with 0.1 pmol of radioactively labeled P1 in a 20 Ml vol and was allowed to hybridize at 45°C for 2 h. Reverse transcription was carried out in a 40 Ml vol at 41°C for 1 h. cDNA products were separated by electrophoresis on 0.4-mm-thick 6% polyacrylamide gels containing 7 M urea, which were exposed to Kodak XAR5 film for 5 d at room temperature. Dideoxynucleotide DNA sequence analysis (24) was performed with oligonucleotide P1 and a fragment of the hCRH gene (11) , which encoded nucleotides 218-417, cloned into the Sma I site of the M13-Bluescribe polylinker (Stratagene), using a-35S-dATP (Amersham Corp.) and DNA polymerase (Sequenase; U.S. Biochemical Corp., Cleveland, OH). This DNA sequence ladder was subjected to electrophoresis on the same gel as were the reverse transcription cDNA products, so that it could serve as a molecular size standard.
RIA of hCRH peptide in placenta. 0.1-1.0 g of human placental tissue was extracted and lyophilized (25 Fig. 2 . A broad band of RNA 1,700 bases in length was detected using the radioactively labeled cRNA probes, hCRH 1 and hCRH2, which are complementary to the 5' and 3' portions of the hCRH gene, respectively (Figs. 1 and 2 A). This same 1,700-nucleotide-long mRNA species appeared to comigrate with rat hypothalamic CRH mRNA (Fig. 2 B) .
The 5' transcriptional initiation site of placental hCRH mRNA was determined by primer extension analysis (Fig. 3 ).
Reverse transcription of placental RNA primed with P1 yielded cDNAs 40-43 nucleotides in length. Whether these cDNAs represent a single initiation site associated with variable reverse transcription, or more than one closely associated cap site is not known. No cDNAs were reverse transcribed in the absence of added RNA (Fig. 3 A) . Thus, hCRH mRNA, isolated from placentae of 40-wk gestation, was found to initiate at nucleotide 334 (as well as possibly at nucleotides 335-337) of the hCRH gene (Fig. 3 B) . This site is 23-26 bases downstream from a potential promoter (26) 10. age. Total RNA was extracted from placentae whose gestational ages varied between 7 and 40 wk. Northern blot analysis of these RNAs, which was performed using the cRNA probe, hCRH 1, is displayed in Fig. 4 (Fig. 4 B) . Selected placental RNA preparations were further analyzed for the expression of hCG-a mRNA (Fig. 4 C) . In contrast to the findings for hCRH mRNA, the 600-base-long hCG-a mRNA was expressed to the greatest extent in RNA that was isolated from first trimester placentae, and was reduced in RNA samples obtained from placentae of later gestational ages. A semiquantitative assessment of the amount of hCRH mRNA and peptide present in placentae of different gestational ages is displayed in Fig. 5 . Compared with first trimester samples, there was more than a 20-fold increase in both hCRH mRNA and peptide during the final 5 wk ofgestation. Low but detectable levels of hCRH mRNA were present in first and second trimester samples, but hCRH peptide could be detected by RIA only in second and third trimester samples.
Discussion
Our results demonstrate that authentic hCRH mRNA is present in human placenta, which strongly implies that the hCRH gene is transcribed in this tissue. Since the initial finding of a CRH-like factor in extracts of human placenta (5), several studies have addressed the structural characterization and biosynthetic source of this factor. This CRH-like substance reacts with anti-CRH antisera in a manner indistinguishable from that of native hCRH (6) (7) (8) (9) . It is also equipotent when compared with native hCRH in bioassay systems (5, 9) , and it comigrates with native CRH during gel exclusion chromatography (6, 7, 9) . Moreover, there is a gradient in immunoreactive plasma hCRH levels across the placenta (7, 9) . Taken together, these data suggest that a form of hCRH that is indistinguishable from hypothalamic CRH is synthesized in human placenta. We now offer compelling evidence in support of this suggestion by the demonstration of both hCRH mRNA and the parallel increase in hCRH mRNA and peptide in human placenta during gestation.
Our results suggest that the structure of placental hCRH mRNA is very similar to that predicted for hypothalamic hCRH mRNA (16 both 5'-and 3'-related CRH genomic sequences are contained within the species of hCRH mRNA that was detected in placenta. Furthermore, our finding that the site of transcriptional initiation of hCRH mRNA, which was isolated from term placenta is at nucleotide 334 of the hCRH gene, is in agreement with Shibahara et al's (16) prediction of the initiation site for hypothalamic hCRH mRNA, which they made based upon the location of a consensus promoter element in the hCRH gene 23 nucleotides upstream from this site (16).
hCRH mRNA is detected in placenta from 7 to 40 wk of gestation, and increases more than 20-fold during the last 5 wk of pregnancy. This increase in placental hCRH mRNA levels coincides with the increase in hCRH peptide content in placental tissue. These findings are consistent with prior studies that demonstrated a progressive rise during gestation in the levels of hCRH peptide in maternal plasma (6-9) and placental tissue (9) . These increases have also been most dramatic during the final 5 wk before delivery. The mechanism underlying the marked degree of gestational variation of hCRH mRNA in placenta is unknown.
In addition to hCRH, hCG, and chorionic somatomammotropin, several other peptide hormones are expressed in the human placenta (27) . These include ACTH (28) , thyrotropinreleasing hormone (29) , gonadotropin-releasing hormone (30) , and somatostatin (31) . The mRNAs that encode some ofthese neuropeptides have also been detected in placenta (32, 33) .
The role of placental CRH in maternal-placental-fetal physiology is not known. Since placental CRH has been shown to be secreted into both the maternal (6-9) and fetal (7) (8) (9) circulations, it could conceivably function to influence the HPA axis ofeither mother or fetus. In fact, the dramatic rise in human fetal cortisol at 34-35 wk of gestation (34) , at a time when placental CRH is also increasing rapidly, is compatible with a role for placental CRH in the regulation of the fetal HPA axis. In this context, hCRH might play a role in parturition, since it has been demonstrated that this event is influenced by fetal glucocorticoid levels in at least some mammalian species (35). Alternatively, in light of the presence of proopiomelanocortin mRNA (32) and ACTH (28) in human placenta, it is possible that placental hCRH may act in a paracrine fashion to regulate placental proopiomelanocortin expression (36) .
There appears to be differential tissue-specific regulation of the hCRH gene in placenta and hypothalamus. In the latter, hCRH mRNA and peptide are expressed at low levels and are negatively regulated by glucocorticoid (3, 4) . In contrast, pla- . 4 I cental hCRH mRNA and peptide increase dramatically during gestation. Furthermore, levels of hCRH in placenta are not negatively regulated by glucocorticoid. In one study (37), pregnant women treated with large doses of the potent glucocorticoid, betamethasone, had no reduction in plasma CRH levels, despite a reduction in plasma ACTH and in cortisol. In a second study (38) , 10-6 M dexamethasone failed to suppress the release of hCRH from perifused placental fragments. CRH is encoded by a single locus on the long arm of chromosome 8 (39) . Thus, the differential regulation of the hCRH gene in placenta and hypothalamus is most likely due to tissue-specific differences in either transacting cellular components, cisacting DNA sequences within the hCRH gene, or to both factors. Elucidation of these differences will aid in the further understanding of the mechanisms of CRH gene regulation.
